UB Therapeutics

About

Headcount over time

Offices

Q&A

What is UB Therapeutics' primary focus?

UB Therapeutics is a biotechnology company developing a novel therapy for the treatment of multiple myeloma.

What type of compound is UB Therapeutics developing?

The company's compound is a cyclic peptide with potential anticancer therapeutic activity, designed to block deubiquitinases and the proteasome.

When was UB Therapeutics founded?

UB Therapeutics was founded in January 2023.

How many employees does UB Therapeutics currently have?

UB Therapeutics has 1-10 employees.

What is the total amount of funding UB Therapeutics has raised to date?

UB Therapeutics has raised a total of $415,415 USD.

When was UB Therapeutics' last funding round and who were the investors?

In February 2023, UB Therapeutics secured funding from NGT HealthCare II and Israel Innovation Authority.

What is UB Therapeutics' current funding stage?

UB Therapeutics is currently in the Pre-Seed funding stage.

Who is the founder of UB Therapeutics?

Ashraf Brik is the founder of UB Therapeutics.

Team · 8

Dima Ghannam-Shahbari

Founder · CEO & Co-Founder

Ashraf Brik

Founder · Co-Founder

Peretz Lavie

Director

Liora Sklair-Tavron

Senior Consultant

Sahar Saadi

Researcher

Zohar Gindler

Director

Nizar Mishael

CFO & Director

Livnat Ben-Zur

Board Member

Sectors & technology

Tags